Removing Jardiance From the Formulary | PBMI 2025

Scripius' decision to remove Jardiance (empagliflozin) from its formulary and replace it with Brenzavvy (bexagliflozin) led to cost savings that were more than twice as large as expected, according to Jennie Barlow, Pharm.D., MBA, associate vice president, pharmacy industry relations.

In an interview at the 2025 Pharmacy Benefit Management Institute Annual National Conference last week in Orlando, Florida, Barlow said the expected savings from the removal of Jardiance was projected to be $1.6 million. "We have actually realized over $3.4 million in savings with this commercial population," she said in an interview with Managed Healthcare Executive.

Scripius, a pharmacy benefit manager owned and operated by the Intermountain Health health system in Salt Lake City, kept Farxiga (dapagliflozin) as a preferred agent in the sodium-glucose cotransporter 2 (SGLT2) class of drugs used to treat diabetes.

"Farxiga will have a loss of exclusivity in 2026 so we really tried to prepare for multisource generics entering the market. We wanted to drive as many members to Farxiga as we could, but then also have an alternative for patients with high deductibles, where they could have a cost-effective opportunity to have glycemic control with Brenzavvy," Barlow said.

Barlow was one of the panelists at a session at the meeting about pharmacy benefits and cardiorenal metabolic disease.